Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

AXTI April 30, 2026

AXT Inc Q1 2026 Earnings Call - Record Backlog and Aggressive Capacity Expansion Drive Path to Profitability

AXT Inc reported a pivotal first quarter for 2026, with revenue jumping to $26.9 million and gross margins rebounding sharply to nearly 30%. The company is riding a massive wave of demand for Indium P...

  • Q1 2026 revenue reached $26.9 million, up from $23.0 million in Q4 2025 and $19.4 million in Q1 2025, driven primarily by Indium Phosphide sales.
  • Non-GAAP gross margin surged to 29.9% in Q1 2026, a significant improvement from 21.5% in Q4 2025 and a negative 6.1% in Q1 2025.
  • Indium Phosphide backlog has hit a record high of over $100 million, reflecting strong demand from AI infrastructure and data center applications.
  • +9 more takeaways
IDA April 30, 2026

IDACORP Q1 2026 Earnings Call - Strong Industrial Load Growth Offsets Mild Weather Headwinds

IDACORP delivered a solid start to 2026, with diluted EPS rising to $1.21 from $1.10 last year, driven by higher retail revenues and strong industrial load ramp-ups from customers like Micron and Meta...

  • First-quarter diluted EPS came in at $1.21, up from $1.10 in the prior year, despite headwinds from higher share dilution and lower accelerated amortization of investment tax credits.
  • Retail revenues increased by $23 million, supported by a January rate increase and steady customer growth across all segments, including a 2.4% rise in residential accounts.
  • Industrial energy sales surged 5.7% year-over-year, driven by the ramp-up of large customers like Micron and Meta, which helped offset a $10.7 million decline in residential and commercial usage caused by mild weather.
  • +7 more takeaways
ASUR April 30, 2026

Asure Software Q1 2026 Earnings Call - AI-Driven Platform Shift and Margin Expansion

Asure Software delivered a strong start to 2026, with Q1 revenue jumping 23% year-over-year to $42.8 million and adjusted EBITDA margins expanding 800 basis points to 29%. The company is executing a d...

  • Q1 2026 revenue surged 23% year-over-year to $42.8 million, driven by strong momentum in its core HCM platform and successful integration of the Lathem acquisition.
  • Adjusted EBITDA margin expanded significantly by 800 basis points to 29%, up from 21% in Q1 2025, reflecting improved operational leverage and cost discipline.
  • Organic growth accelerated to 7% in Q1 2026, a notable pickup from 3% and 3.5% in the prior two years, signaling renewed momentum in a historically seasonal quarter.
  • +7 more takeaways
FSLR April 30, 2026

First Solar Q1 2026 Earnings Call - Record Revenue, CuRe Launch, and Policy-Driven Pricing Power

First Solar delivered a record start to 2026, posting $1 billion in Q1 revenue and $520 million in adjusted EBITDA, driven by a 31% volume surge and a 60% EBITDA margin. The company’s CuRe technology ...

  • Record Q1 2026 revenue of $1 billion, up 24% year-over-year, driven by a 31% increase in module volume.
  • Adjusted EBITDA of $520 million exceeded the high end of the preview range, reflecting a 60% margin and 6 percentage point gross margin expansion.
  • CuRe technology launch is complete at Perrysburg, with a ramp across the Series 6 and 7 fleet expected to generate up to $600 million in additional revenue via technology adjusters in 2027 and 2028.
  • +9 more takeaways
ARDX April 30, 2026

Ardelyx Q1 2026 Earnings Call - IBSRELA Revenue Surges 58% as Company Targets $1B Peak

Ardelyx delivered a sharp commercial breakout in Q1 2026, with IBSRELA revenue jumping 58% year-over-year to $70.1 million, while XPHOZAH revenue held steady at $23.3 million after adjusting for a pri...

  • IBSRELA Q1 2026 revenue surged 58% year-over-year to $70.1 million, driven by increased prescriber breadth, deeper prescribing, and improved patient pull-through.
  • XPHOZAH Q1 2026 revenue was $23.3 million; underlying paid prescription revenue grew 19% year-over-year after excluding a $3.8 million favorable return reserve adjustment from Q1 2025.
  • Full-year 2026 revenue guidance reiterated: IBSRELA $410–$430 million (50–57% growth) and XPHOZAH $110–$120 million, supporting a long-term $1 billion IBSRELA peak by 2029.
  • +7 more takeaways
EXPO April 30, 2026

Exponent Inc Q1 2026 Earnings Call - AI and Physical Systems Drive Revenue Growth

Exponent Inc reported strong Q1 2026 results with double-digit revenue and earnings growth, driven by surging demand for user research and risk management as AI integrates into consumer electronics, r...

  • Q1 2026 net revenues rose 14% year-over-year to $166.3 million, while net revenues before reimbursements grew 10% to $151.8 million, reflecting strong demand across consumer electronics, utility risk management, and reactive failure analysis.
  • Net income increased 11% to $29.6 million, and diluted EPS rose 13% to $0.59, demonstrating consistent profitability expansion despite macroeconomic headwinds and rising operational costs.
  • EBITDA grew 15% to $43.1 million, achieving a margin of 28.4% of net revenues, up from 27.3% in the prior year period, driven by leverage on billable hours and realized rate increases.
  • +7 more takeaways
WDC April 30, 2026

Western Digital Q2 Fiscal 2026 Earnings Call - Agentic AI and UltraSMR Drive Margin Expansion

Western Digital delivered a quarter of structural acceleration. Revenue jumped 45% year over year to $3.3 billion while gross margin breached 50% for the first time. The company shipped 222 exabytes o...

  • Revenue surged 45% year over year to $3.3 billion, driven by strong cloud demand and improved pricing across all end markets.
  • Gross margin expanded 1,040 basis points year over year to 50.5%, marking the first time the company has breached the 50% threshold.
  • Cloud revenue represented 89% of total sales at $3 billion, up 48% year over year, as hyperscalers scaled storage for AI workloads.
  • +7 more takeaways
WHG April 30, 2026

Westwood Holdings Group Q1 2026 Earnings Call - AUM Surges to $18.3B as Energy and Private Capital Drive Growth

Westwood Holdings Group reported a solid quarter marked by strategic AUM growth and a pivot toward structural, non-market-dependent capital streams. Assets under management climbed to $18.3 billion, u...

  • Firm-wide AUM grew to $18.3 billion from $17.4 billion at year-end 2025, driven primarily by structural growth in energy and real asset strategies rather than market appreciation.
  • The ETF suite surpassed $315 million in combined assets, with West Two closing over $300 million and West Three fundraising actively underway.
  • Institutional and intermediary gross sales totaled approximately $529 million, highlighted by the onboarding of Westwood’s first institutional Managed Investment Solutions client.
  • +7 more takeaways
TRUP April 30, 2026

Trupanion Q1 2026 Earnings Call - Adjusted Operating Income Surges 29% as Company Pivots to New Digital-First Product

Trupanion delivered a strong first quarter, with adjusted operating income jumping 29% year-over-year to $40.2 million, driven by a record 14.2% subscription margin and resilient retention at 98.35%. ...

  • Adjusted operating income reached $40.2 million, up 29% year-over-year, signaling robust core earnings power and fueling future growth investments.
  • Subscription adjusted operating margin hit a record 14.2% in Q1, expanding 130 basis points year-over-year despite veterinary cost inflation.
  • Total revenue grew 12% to $384 million, with subscription revenue up 16% to $269.5 million, exceeding the high end of management expectations.
  • +7 more takeaways
CERS April 30, 2026

Cerus Corporation Q1 2026 Earnings Call - Revenue Guidance Raised on Strong Platelet and IFC Demand

Cerus Corporation delivered a robust first quarter in 2026, with product revenue surging 24% to $53.7 million. The company raised its full-year product revenue guidance to $227 million-$231 million, d...

  • Product revenue grew 24% year-over-year to $53.7 million in Q1 2026, driven by strong platelet franchise performance and accelerating U.S. IFC demand.
  • Full-year 2026 product revenue guidance was raised to $227 million-$231 million, reflecting increased conviction in underlying demand for INTERCEPT.
  • U.S. IFC revenue surged approximately 90% year-over-year to $5.7 million, with therapeutic dose equivalents increasing 120% as the company shifts to a kit-based sales model.
  • +12 more takeaways